Canada authorizes AstraZeneca drug Evusheld for COVID prevention
Evaluations and proposals are unbiased and merchandise are independently chosen. Postmedia could earn an affiliate fee from purchases made by hyperlinks on this web page.
Article content material
OTTAWA — Well being Canada has accredited AstraZeneca’s antibody mixture to stop symptomatic COVID-19 an infection in immunocompromised individuals.
Commercial 2
Article content material
The drug, named Evusheld, is meant for individuals who can not obtain a typical vaccine or for whom vaccines alone received’t present sufficient immunity.
The drug was not accredited as an alternative to vaccination towards COVID-19 for most individuals.
“Each the Public Well being Company of Canada and Well being Canada proceed to strongly advocate up-to-date vaccination for all eligible Canadians,” Well being Canada mentioned in a information launch Thursday.
Whereas a vaccine successfully teaches the physique to make its personal antibodies over a brief time frame, AstraZeneca’s product delivers ready-made antibodies to right away begin preventing off the virus.
The antibodies are delivered as two separate injections,earlier than publicity to COVID-19.
Commercial 3
Article content material
Drug trial knowledge launched in November confirmed an 83% discount within the threat of creating symptomatic COVID-19, in comparison with a placebo after about six months.
“For weak populations, resembling those that are immune-compromised, Evusheld helps to deal with an unmet want within the ongoing struggle towards COVID-19,” mentioned Kiersten Combs, president of AstraZeneca Canada.
“It’s an attention-grabbing antibody and may be helpful in individuals like transplant sufferers or those that have hematologic malignancies who, regardless of vaccination, won’t ever get a very good immune response,” mentioned Dr. Sumon Chakrabarti, an infectious illnesses doctor at Trillium Well being Companions in Mississauga.
“The query although is, how lengthy will or not it’s helpful because the virus appears to shortly adapt to those antibodies and have the ability to evade them. Although it seems like with this antibody, it would most likely have pretty sturdy exercise for some time earlier than the virus is ready to sidestep it,” Chakrabarti mentioned.
Commercial 4
Article content material
Canada has already signed an settlement with AstraZeneca to obtain 100,000 doses this 12 months.
Well being Canada has positioned circumstances on the drug’s approval, together with a requirement for AstraZeneca to repeatedly present up to date info on the security and efficacy of the antibody mixture.
The company mentioned lab research present Evusheld is predicted to neutralize BA.2, a sublineage of the Omicron variant of COVID-19, which is operating rampant in communities throughout Canada.
The corporate says well being professionals ought to think about providing a bigger dose of the antibodies in areas the place Omicron is circulating.
AstraZeneca has been learning the mix as a possible therapy for COVID-19 as properly, although the drug has not been accredited for that use.
– with recordsdata from Anthony Furey
